XXXX sec.gov to today. links is year, other our Thank the you, fiscal -- year. filed our the of as in the I’m XXXX Nasrat, the our quarter June year elitepharma.com well Investor filings. ended for a first XX calling XX-Q [ph] thanks the on XX-Q sorry and Yesterday, and XX, so March XXXX. XX, The the quarter everyone fiscal [ph] to websites that June many We're quarter of we fiscal ended available March is as on website, section provide
If you comments some and insight questions On and to and the any through we best or do shareholders Elite I’ll Q context questions from my of into the please through those the as and the of gone you are have extra sites. always copy yet, analysis, numbers, elitepharma.com usual some related. that financials briefly haven’t take and financials received followers address the from parts to providing get other key of a
September regulations, after usually our August time quarterly filings Q on due have the per is got on are that this the calls the SEC I next of investor First, The and as timing we on yesterday that we [ph] quarter quarterly filing the the that and day. all And end usual so X, works. means question days the filed next filing that’s on on November our due Monday. November closer, it It’s the we’ll but calls X, November XX XX, on is for and how get will which XX as of you I make but is timing investor regulations. Friday, which this, due be too, based a all in a expect for generally SEC announcement as quarter that’s always, one that was
due this XXX why our million notably, shares, back put that shares were than sheet. did convertible is of in the they years, shares. on he Series There were XXX three it quarter, question least to that this we request a Hakim million go are I company. shares. increase that to not number to financials, ago. received same common that June shares, J can on million And the shares Preferred have why this into he Nasrat Elite exchange, number returning owns. [Indiscernible] year issued into so effective Most and happened more shares was he Stock shares at roughly returned of of were are outstanding March issued the In May can how is and question Elite into starting wait past with retired XXXX restrictions shares. to shares when number shares but convert The authorized little onto conversion XXXX, in only and exact if stock, And common Now of has of and in the Nasrat a down? back the XXX company an XX, decreased? shareholders on These approved the balance of shares why have number We the he
funding naturally to you’ll Preferred financial more It’s a note of into line with million lot shares been $XX J was Series equity Shares, there’s and shares them the balance a the brought the enter activities. on Lincoln has the also and they the which are statements so of XX recorded to yesterday. important Park, note it for Nasrat’s us this that sheet, enabled details. return as number So product development see on down outstanding of ongoing giving the Q mezzanine the issued equity,
Those a the this $X.X year increase The quarter mostly last well was the Methadone for of XX, that on in there a XXXX and listening us you quarter and there’s quarters June sales of for years, year-to-year clear and for for Naltrexone year, Revenues compared of time to reading and are million related basis. were these that Ks million reason P&L. not due Phentermine, variances the last onto as Phentermine as our were that’s as Now the June the been Qs calls strong ended XX% have Naltrexone increase most some over following $X.X to Naltrexone, to especially will reading who our revenues year. note to and a this.
top batches to products. variations Naltrexone which but of effect an to therefore product, period. from With expensive to it's expensive Phentermine, a revenues in few and an extra that’s product. product, varies First an Naltrexone line batches regard of than all, is a other volume An is a large few period on or less material, it expensive not has
There’s zero. sales which and compare mentioned, contributing to has this products also therefore increase and and them effect large. out. they last revenues, products had us smooth these We revenues trend high are That high-cost some overall year, product, this So to Methadone increase just the when had overall that percentage very year's for on I any revenues products. quarterly was an year. Last obviously in respect the we we you observing last volume The to periods. zero, that’s growth variation specific the an to were brings Overtime with Methadone. revenues,
manufacture this of proactively owned ANDA. is to situation Elite’s product. FDA largest that by and year its We product our years was that’s Methadone, it be last alliance of customer contract, facility. with week. it, manufacture that we The for product marketing this the is have in manufactured decreased future. in Glenmark, more product has manufacturing. We business. included customer Methadone, This contract there orders this the near the own one was ANDA by ANDA was is distributing it’s Few own our Now you and addressed nature contract approved last so the own revenue, moved ago, we filing our from no stream will as to it, the the there however, manufacturing the a but that own expired, And customer this who our production contract just Methadone
into term. Now commercial commenced, Methadone expect it in and of market the production back the launch to Glenmark short has we with
to an revenues, I'm will case. have profits quarter, we It improvement is old We will a manufacturing back revenue which that own will manufacturing no announced, share be most but will is Glenmarks our product importantly, contract but not which definitely and product so and we’ll contract this to wasn’t it from June This have of the is was the that, just approved the to now future it a sales. we situation. new effect online. market online, be coming from contributor a earned is similar be that Methadone increases, product earned margin receiving expecting now manufacturing by in so over XX, be back June earning This the coming had product on
down R&D which as of year-to-year compared the P&L for to June Moving XXXX million for the a quarter were decrease to XXXX, X X.X XX%. June that’s million expenses
are the I pharmaceutical the said comes that addition, benefit and when with are for especially the costs just That's spent FDA. the expensed by being revenues future. it’s realized as and is dealing as R&D Now spent in accounting numerous achieved are they the it times, these amount rules, only but incurred what true being as in on, period costs important in from required which activities is us the a business and to
moving We’ve here, the the as production our products of incurred now, expect currently. R&D at to to more short filed lifeblood on begin of money least of generic approvals this which for related with exception just I’m in were online will from and away costs and Isradipine medium fashion. benefiting process and the FDA and got. month. to year, year's and XX-Ks in is additional These products products cost pharmaceutical were to one incurred that all reported spent no only beginning during benefiting there the from last is sure. through June as Elite of we well development have and as have And these year, is can Generic FDA as all the term. last efforts in cost through XXXX Our prior currently us year, us last to this Take XX-Qs. products this Facility four Percocet overwork for The two The Transfer approved Nasrat Dantrolene that well, benefits a costs quarter. and last quarter file just say all the those come of companies ago. Loxapine that the year the as Methadone we more cost filed see being the prior similar are in rule. will are were next you ANDA Northvale
product in invest and most importantly, products being approved to hopefully continue will continue, the development, FDA. by We our have to
All diversity of result larger the so that’s improvement will a in R&D increase this and from in our in value, take away spend. line, stream, broader revenue and shareholder product
on million. year of we for million as Finally a the operating loss compared P&L, net to last net loss June a quarter XXXX of had $X.X the $X.X
So Elite of generics products or in still transferred or approvals it's year, profitability’s. of product path an to we additional increased improvement and recent the and with over to profitability or plan the it’s the FDA and these developed and the process, loss pipeline a last alliance being review to revenues revenues, back products how but being requires achieve Glenmark,
much One schedule se, plan, appointment for newest last right and and place we plan. and our We’re it’s on nonetheless. Aqeel. Aqeel XX-Q of and skill financial director, of plan a are executing background this Aqeel’s item so per both Fatmi. time, experience significant but this we’re to continue right And thing, Mr. not of this Elite person really that’s for right the sets execute
Aqeel So we working welcome him. we and forward look to all with to Elite
Hakim an Chairman would Officer, update and comments. give our and Chief his Now, Nasrat Mr. to Executive like
